Kava monograph: A clinical decision support tool

Journal of Herbal Pharmacotherapy

Volumn 2, Issue 4, 2002, Pages 65-91

  Ulbricht, Catherine ^a   Basch, Ethan ^a   Hammerness, Paul ^a   Tsouronis, Candy ^a   Sollars, David ^a   Rogers, Adrianne ^a   Basch, Samuel ^a   Bent, Steve ^a   Boon, Heather ^a   Ernst, Edzard ^a  

^a Natural Standard   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; ANESTHETIC AGENT; ANTITHROMBOCYTIC AGENT; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE DERIVATIVE; CENTRAL DEPRESSANT AGENT; DOPAMINE; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; DROPERIDOL; HALOPERIDOL; HERBACEOUS AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPERICUM PERFORATUM EXTRACT; ISONIAZID; KAVA EXTRACT; KAWAIN; LEITAN; MELATONIN; METHOTREXATE; METOCLOPRAMIDE; MONOAMINE OXIDASE INHIBITOR; PARACETAMOL; PHENELZINE; PLACEBO; SEDATIVE AGENT; TRANYLCYPROMINE; TRYPTOPHAN; TYRAMINE; UNINDEXED DRUG; VALERIAN;

ANXIETY DISORDER; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DECISION SUPPORT SYSTEM; DOSE RESPONSE; DRUG ABSORPTION; DRUG ALCOHOL INTERACTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG SAFETY; EXTRAPYRAMIDAL SYMPTOM; EYE DISEASE; FOOD DRUG INTERACTION; GASTROINTESTINAL DISEASE; HEMATOLOGIC DISEASE; HUMAN; KIDNEY DISEASE; LIVER TOXICITY; LUNG DISEASE; MEDICAL DECISION MAKING; MEDICAL LITERATURE; MENTAL DISEASE; MUSCULOSKELETAL DISEASE; NEUROLOGIC DISEASE; NONHUMAN; PHARMACOLOGICAL PARAMETERS; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; SKIN ALLERGY; SKIN DISEASE; TREATMENT CONTRAINDICATION;

EID: 0036426316     PISSN: 15228940     EISSN: None     Source Type: Journal    
DOI: 10.1300/J157v02n04_07     Document Type: Article

References (93)

1. Russmann S, Lauterburg BH, Helbling A. Kava hepatotoxicity. Ann Intern Med 2001; 135 (1): 68-69.
2. Escher M, Desmeules J, Giostra E, et al. Hepatitis associated with Kava, a herbal remedy for anxiety. BMJ 2001; 322 (7279): 139.
3. Kraft M, Spahn TW, Menzel J, et al. [Fulminant liver failure after administration of the herbal antidepressant Kava-Kava]. Dtsch Med Wochenschr 2001; 126 (36): 970-972.
4. Center for Food Safety and Applied Nutrition (US Food and Drug Administration). Kava-containing dietary supplements may be associated with severe liver injury (document issued March 25, 2002).
5. Center for Food Safety and Applied Nutrition (US Food and Drug Administration). Letter to health care professionals: FDA issues consumer advisory that kava products may be associated with severe liver injury (document issued March 25, 2002). Contact information for FDA Medwatch program: 1-800-332-1088.
6. De Leo V, La Marca A, Lanzetta D, et al. [Assessment of the association of Kava-Kava extract and hormone replacement therapy in the treatment of postmenopause anxiety]. Minerva Ginecol 2000; 52 (6): 263-267.
7. Cawte J. Parameters of kava used as a challenge to alcohol. Aust N Z J Psychiatry 1986; 20 (1): 70-76.
8. Gleitz J, Friese J, Beile A, et al. Anticonvulsive action of (+/-)-kavain estimated from its properties on stimulated synaptosomes and Na+ channel receptor sites. Eur J Pharmacol 1996; 315 (1): 89-97.
9. Schmitz D, Zhang CL, Chatterjee SS, et al. Effects of methysticin on three different models of seizure like events studied in rat hippocampal and entorhinal cortex slices. Naunyn Schmiedebergs Arch Pharmacol 1995; 351 (4): 348-355.
10. Baum SS, Hill R, Rommelspacher H. Effect of kava extract and individual kavapyrones on neurotransmitter levels in the nucleus accumbens of rats. Prog Neuropsychopharmacol Biol Psychiatry 1998; 22 (7): 1105-1120.
11. Steiner GG. The correlation between cancer incidence and kava consumption. Hawaii Med J 2000; 59 (11): 420-422.
12. Singh YN. Effects of kava on neuromuscular transmission and muscle contractility. J Ethnopharmacol 1983; 7 (3): 267-276.
13. Kinzler E, Kromer J, Lehmann E. [Effect of a special kava extract in patients with anxiety-, tension-, and excitation states of non-psychotic genesis. Double blind study with placebos over 4 weeks]. Arzneimittelforschung 1991; 41 (6): 584-588.
14. Warnecke G. [Psychosomatic dysfunctions in the female climacteric. Clinical effectiveness and tolerance of Kava Extract WS 1490]. Fortschr Med 1991; 109 (4): 119-122.
15. Volz HP, Kieser M. Kava-kava extract WS 1490 versus placebo in anxiety disorders-a randomized placebo-controlled 25-week outpatient trial. Pharmacopsychiatry 1997; 30 (1): 1-5.
16. Pittler MH, Ernst E. Efficacy of kava extract for treating anxiety: systematic review and meta-analysis. J Clin Psychopharmacol 2000; 20 (1): 84-89.
17. Mathews JD, Riley MD, Fejo L, et al. Effects of the heavy usage of kava on physical health: summary of a pilot survey in an aboriginal community. Med J Aust 1988; 148 (11): 548-555.
18. Singh YN. Kava: an overview. J Ethnopharmacol 1992; 37 (1): 13-45.
19. Spillane PK, Fisher DA, Currie BJ. Neurological manifestations of kava intoxication. Med J Aust 1997; 167 (3): 172-173.
20. Meyer HG. Pharmakologie der wirksamen prinzipien de kawarhizoms (Piper methysticum Forst.). Arch Int Pharmacodyn Ther 1962; 138: 505-536.
21. Jappe U, Franke I, Reinhold D, et al. Sebotropic drug reaction resulting from kava-kava extract therapy: a new entity? J Am Acad Dermatol 1998; 38 (1): 104-106.
22. Schmidt P, Boehncke WH. Delayed-type hypersensitivity reaction to kava-kava extract. Contact Dermatitis 2000; 42 (6): 363-364.
23. Suss R, Lehmann P. [Hematogenous contact eczema caused by phytogenic drugs exemplified by kava root extract]. Hautarzt 1996; 47 (6): 459-461.
24. Siegers CP, Honold E, Krall B, et al. Results of the drug monitoring L 1090 with Laitan capsules. Arztl Forsch 1992; 39: 7-11.
25. Norton SA, Ruze P. Kava dermopathy. J Am Acad Dermatol 1994; 31 (1): 89-97.
26. Ruze P. Kava-induced dermopathy: a niacin deficiency? Lancet 1990; 335 (8703): 1442-1445.
27. Keller F, Klohs M. A review of the chemistry and pharmacology of the constituents of Piper methysticum. Lloydia 1963; 26: 1-15.
28. Holm E, Staedt U, Heep J, et al. [The action profile of D,L-kavain. Cerebral sites and sleep-wakefulness-rhythm in animals]. Arzneimittelforschung 1991; 41 (7): 673-683.
29. Munte TF, Heinze HJ, Matzke M, et al. Effects of oxazepam and an extract of kava roots (Piper methysticum) on event-related potentials in a word recognition task. Neuropsychobiology 1993; 27 (1): 46-53.
30. Gessner B, Cnota P. Extract of the kava-kava rhizome in comparison with diazepam and placebo. Z Phytother 1994; 15 (1): 30-37.
31. Johnson D, Frauendorf A, Stecker K, et al. Neurophysiological active profile and tolerance of kava extract WS 1490, A pilot study with randomized evaluation. TW Neurolgie Psychiatrie 1991; 5 (6): 349-354.
32. Herberg KW. Driving ability after intake of kava special extract WS 1490, a double-blind, placebo-controlled study with volunteers. Zeitschrift fr̈ Allgemeinmedizin 1991; 13: 842-846.
33. Herberg KW. [Effect of Kava-Special Extract WS 1490 combined with ethyl alcohol on safety-relevant performance parameters]. Blutalkohol 1993; 30 (2): 96-105.
34. Almeida JC, Grimsley EW. Coma from the health food store: interaction between kava and alprazolam. Ann Intern Med 1996; 125 (11): 940-941.
35. Prescott J, Jamieson D, Emdur N, et al. Acute effects of kava on measures of cognitive performance, physiological function and mood. Drug Alc Rev 1993; 12: 49-58.
36. Saletu B, Grn̈berger J, Linzmayer L, et al. EEG-brain mapping, psychometric and psychophysiological studies on central effects of kavain-a kava plant derivative. Hum Psychopharm 1989; 4: 169-190.
37. Schelosky L, Raffauf C, Jendroska K, et al. Kava and dopamine antagonism. J Neurol Neurosurg Psychiatry 1995; 58 (5): 639-640.
38. Garner LF, Klinger JD. Some visual effects caused by the beverage kava. J Ethnopharmacol 1985; 13 (3): 307-311.
39. Strahl S, Ehret V, Dahm HH, et al. [Necrotizing hepatitis after taking herbal remedies]. Dtsch Med Wochenschr 1998; 123 (47): 1410-1414.
40. Douglas W. The effects of heavy usage of kava on physical health. Med J Australia 1988; 149: 341-342.
41. Stafford N. Germany may ban kava kava herbal supplement. Reuter's News Service Germany (November 19, 2001).
42. Scherer J. Kava-kava extract in anxiety disorders: an outpatient observational study. Adv Ther 1998; 15 (4): 261-269.
43. Donadio V, Bonsi P, Zele I, et al. Myoglobinuria after ingestion of extracts of guarana, Ginkgo biloba and kava. Neurol Sci 2000; 21 (2): 124.
44. Gleitz J, Beile A, Wilkens P, et al. Antithrombotic action of the kava pyrone (+)-kavain prepared from Piper methysticum on human platelets. Planta Med 1997; 63 (1): 27-30.
45. Jamieson DD, Duffield PH, Cheng D, et al. Comparison of the central nervous system activity of the aqueous and lipid extract of kava (Piper methysticum). Arch Int Pharmacodyn Ther 1989; 301: 66-80.
46. Jamieson DD, Duffield PH. Positive interaction of ethanol and kava resin in mice. Clin Exp Pharmacol Physiol 1990; 17 (7): 509-514.
47. Davies LP, Drew CA, Duffield P, et al. Kava pyrones and resin: studies on GABAA, GABAB and benzodiazepine binding sites in rodent brain. Pharmacol Toxicol 1992; 71 (2): 120-126.
48. Jussofie A, Schmiz A, Hiemke C. Kavapyrone enriched extract from Piper methysticum as modulator of the GABA binding site in different regions of rat brain. Psychopharmacology (Berl) 1994; 116 (4): 469-474.
49. Uebelhack R, Franke L, Schewe HJ. Inhibition of platelet MAO-B by kava pyrone-enriched extract from Piper methysticum Forster (kava-kava). Pharmacopsychiatry 1998; 31 (5): 187-192.
50. Murphy JM. Preoperative considerations with herbal medicines. AORN J 1999; 69 (1): 173-8, 180.
51. Beckman SE, Sommi RW, Switzer J. Consumer use of St. John's wort: a survey on effectiveness, safety, and tolerability. Pharmacotherapy 2000; 20 (5): 568-574.
52. Duffield AM, Lidgard RO, Low GK. Analysis of the constituents of Piper methysticum by gas chromatography methane chemical ionization mass spectrometry. New constituents of kava resin. Biomed Environ Mass Spear 1986; 13: 305-313.
53. Duffield AM, Lidgard RO. Analysis of kava resin by gas chromatography and electron impact and methane negative ion chemical ionization mass spectrometry. New trace constituents of kava resin. Biomed Environ Mass Spectr 1986; 13: 621-626.
54. Duve RN. Gas-liquid chromatographic determination of major constituents of Piper methysticum. Analyst 1981; 106: 160-165.
55. Klohs MW, Keller F, Williams RE, et al. A chemical and pharmacological investigation of Piper methysticum Forst. J Med Pharm Chem 1959; 1 (1): 95-103.
56. Smith RM. Kava lactones in Piper methysticum from Fiji. Phytochemistry 1983; 22: 1055-1056.
57. Smith RM, Thakrar H, Arowolo A, et al. High-performance liquid chromatography of kava lactones from Piper methysticum. J Chromatography 1984; 283: 303-308.
58. Young RL, Hylin JW, Plucknett DL, et al. Analysis for kawa pyrones in extracts of piper methysticum. Phytochemistry 1966; 5: 795-798.
59. Brüggemann F, Meyer HJ. Die analgetische wirkung der Kawa-inhaltsstoffe dihydrokawain und dihydromethysticin. Arzneimittelforschung 1963; 13: 407-409.
60. Hänsel R. Characterization and physiological activity of some Kawa constituents. Pacific Science 1968; 22: 293-313.
61. Kretzschmar R, Meyer HJ. [Comparative studies on the anticonvulsant activity of the pyrone compounds of Piper methysticum Forst]. Arch Int Pharmacodyn Ther 1969; 177 (2): 261-277.
62. Kretzschmar R, Meyer HJ, Teschendorf HJ. Strychnine antagonistic potency of pyrone compounds of the kavaroot (Piper methysticum Forst.). Experientia 1970; 26 (3): 283-284.
63. Kretzschmar R, Teschendorf HJ, Ladous A, et al. On the sedative action of the kava rhizome (Piper methyst.). Acta Pharmacol Toxicol 1971; 29 (4): 26.
64. Meyer HJ. [Spasmolytic effect of dihydromethysticin, a constituent of Piper methysticum Forst]. Arch Int Pharmacodyn Ther 1965; 154 (2): 449-467.
65. Meyer HJ, Meyer-Burg J. Hemmung des elektrokrampfes durch die kawapyrone dihydromethysticin und dihydrokawain. Arch Int Pharmacodyn 1964; 148 (1-2): 97-110.
66. Singh Y, Blumenthal M. Kava: an overview. Distribution, mythology, botany, culture, chemistry and pharmacology of the South Pacific's most revered herb. Herbal Gram 1997; 39 (Suppl 1): 34-56.
67. Backhauss C, Krieglstein J. Extract of kava (Piper methysticum) and its methysticin constituents protect brain tissue against ischemic damage in rodents. European Journal of Pharmacology 1992; 215 (2-3): 265-269.
68. Kleiser B, Diepers M, Wagner N, et al. Treatment of intracerebral hematomas with kava in rats. Neurology 1998; 50 (4): a398.
69. Walden J, von Wegerer J, Winter U, et al. Effects of kawain and dihydromethysticin on field potential changes in the hippocampus. Prog Neuropsychopharmacol Biol Psychiatry 1997; 21 (4): 697-706.
70. Walden J, von Wegerer J, Winter U, et al. Actions of kavain and dihydromethysticin on ipsapirone-induced field potential changes in the hippocampus. Human Psychopharm 1997; 12: 265-270.
71. + channels. Planta Med 1996; 62: 580-581.
72. Magura EI, Kopanitsa MV, Gleitz J, et al. Kava extract ingredients, (+)-methysticin and (+/-)-kavain inhibit voltage-operated Na(+)-channels in rat CA1 hippocampal neurons. Neuroscience 1997; 81 (2): 345-351.
73. Seitz U, Schule A, Gleitz J. [3H]-monoamine uptake inhibition properties of kava pyrones. Planta Med 1997; 63 (6): 548-549.
74. Emser W, Bartylla K. Improvement of sleep quality. Effect of kava extract WS 1490 on the sleep pattern in healthy subjects. Neurologie/Psychiatrie 1991; 5 (11): 636-642.
75. Gleitz J, Beile A, Peters T. (+/-)-kavain inhibits the veratridine- and KC1-induced increase in intracellular Ca2+ and glutamate-release of rat cerebrocortical synaptosomes. Neuropharmacology 1996; 35 (2): 179-186.
76. Boonen G, Ferger B, Kuschinsky K, et al. In vivo effects of the kavapyrones (+)-dihydromethysticin and (+/-) kavain on dopamine, 3,4-dihydroxyphenylacetic acid, serotonin and 5-hydroxyindoleacetic acid levels in striatal and cortical brain regions. Planta Med 1998; 64 (6): 507-510.
77. Buckley JP, Furgiuele AR, O'Hara MJ. Pharmacology of kava. Ethnopharm Search Psych Drugs 1967; 1: 141-151.
78. Furgiuele AR, Kinnard WJ, Aceto MD, et al. Central activity of aqueous extracts of Piper methysticum (kava). J Pharm Sci 1965; 54: 247-252.
79. Jamieson DD, Duffield PH. The antinociceptive actions of kava components in mice. Clin Exp Pharmacol Physiol 1990; 17 (7): 495-507.
80. Duffield PH, Jamieson D. Development of tolerance to kava in mice. Clin Exp Pharmacol Physiol 1991; 18 (8): 571-578.
81. Duffield AM, Jamieson DD, Lidgard RO, et al. Identification of some human urinary metabolites of the intoxicating beverage kava. J Chromatogr 1989; 475: 273-281.
82. Bhate H, Gerster G, Gracza E. Orale Prämedikation mit Zubereitungen aus Piper methysticum bei operativen Eingriffen in Epiduralanästhesie. Erfahrungsheilkunde 1989; 6: 339-345.
83. Lehmann E, Kinzler E, Friedemann J. Efficacy of a special Kava extract (Piper methysticum) in patients with states of anxiety, tension and excitedness of non-mental origin-a double-blind placebo-controlled study of four weeks treatment. Phytomedicine 1996; 3 (2): 113-119.
84. Singh NN, Ellis CR, Sharp I, et al. A 4-week randomized, double-blind, placebo-controlled study to investigate the effectiveness and safety of Kavatrol was conducted in a non-clinical sample with anxiety and stress (Natrol data, 1977).
85. Malsch U, Kieser M. Efficacy of kava-kava in the treatment of non-psychotic anxiety, following pretreatment with benzodiazepines. Psychopharm. 2001; 157 (3): 277-283.
86. Volz HP. Die anxiolytische wirksmkeit von Kava-spezialextrakt WS 1490 unter langzeittherapie-eine randomisierte doppelblindstudie. Zeit Phytother 1992; 5 (6): 214-222.
87. De L, V, La Marca A, Morgante G, et al. Evaluation of combining kava extract with hormone replacement therapy in the treatment of postmenopausal anxiety. Maturitas 2001; 39 (2): 185-188.
88. Lehmann E, Klieser E, Klimke A, et al. The efficacy of Cavain in patients suffering from anxiety. Pharmacopsychiatry 1989; 22 (6): 258-262.
89. Lindenberg D, Pitule-Schodel H. [D,L-kavain in comparison with oxazepam in anxiety disorders. A double-blind study of clinical effectiveness]. Fortschr Med 1990; 108 (2): 49-53.
90. Wheatley D. Kava and valerian in the treatment of stress-induced insomnia. Phytother Res 2001; 15: 549-551.
91. Woelk H, Kapoula O, Lehrl S, et al. [Treatment of patients suffering from anxiety-double-blind study: kava special extract versus benzodiazepines]. Z Allg Med 1993; 69: 271-277.
92. Pfeiffer CC, Murphree HB, Goldstein L. Effect of kava in normal subjects and patients. Psychopharmacol Bull 1967; 4 (3): 12.
93. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin. Trials 1996; 17 (1): 1-12.